HEPA - Hepion Pharma to begin CRV431 testing in COVID-19 patients

The FDA has signed off investigational new drug application for Hepion Pharmaceuticals' ([[HEPA]] -2.4%) CRV431, a cyclophilin inhibitor for the treatment of COVID-19, and the candidate is poised to move directly into Phase 2 study."Although Hepion's focus and lead indication remain squarely on the treatment of NASH, this IND may allow us opportunities to seek collaboration partnerships to support the initiation of Phase 2 studies of CRV431 for COVID-19, and to explore sources of non-dilutive external funding for our COVID-19 program.", said Robert Foster, Hepion's CEO.In preclinical study, CRV431 demonstrated positive antiviral activity against SARS-CoV-2, and showed to inhibit production of infectious virus with almost five-times greater potency than the positive control compound in the study.

For further details see:

Hepion Pharma to begin CRV431 testing in COVID-19 patients